SS
RNAM

Steve Schonfeld’s Avidity Biosciences RNAM Stock Holding History

Steve Schonfeld’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-439,812
Closed -$31.7M – 2603
2025
Q4 		$31.7M Buy
+439,812
New +$28.4M 0.14% 112
2024
Q3 		– Sell
-5,573
Closed -$228K – 2362
2024
Q2 		$228K Buy
+5,573
New +$160K ﹤0.01% 1775
2024
Q1 		– Sell
-130,117
Closed -$1.18M – 2347
2023
Q4 		$1.18M Buy
130,117
+2,817
+2% +$18.8K 0.01% 975
2023
Q3 		$812K Sell
127,300
-7,699
-6% -$66.3K 0.01% 1079
2023
Q2 		$1.5M Buy
+134,999
New +$1.69M 0.01% 859
2023
Q1 		– Sell
-10,700
Closed -$237K – 2565
2022
Q4 		$237K Buy
+10,700
New +$160K ﹤0.01% 1909
2022
Q1 		– Sell
-19,531
Closed -$464K – 2878
2021
Q4 		$464K Buy
+19,531
New +$466K ﹤0.01% 1300
2021
Q1 		– Sell
-49,110
Closed -$1.25M – 2073
2020
Q4 		$1.25M Buy
+49,110
New +$1.43M 0.02% 732

Other funds holding RNAM

CC
Corsicana & Co Corsicana, Texas $206M AUM 26.42% 1-Year Est. Return

Steve Schonfeld's RNAM Position: Q1 2026 in Review

Steve Schonfeld sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 439,812 shares — an estimated $31.7M sold.

Steve Schonfeld first reported a position in RNAM in Q4 2020 and held it in 8 quarters. The position peaked at $31.7M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

  • Steve Schonfeld reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
  • Steve Schonfeld sold 439,812 Avidity Biosciences shares in Q1 2026, an estimated $31.7M.
  • Steve Schonfeld first reported a position in Avidity Biosciences in Q4 2020 and held it in 8 quarters.
  • Steve Schonfeld's Avidity Biosciences position peaked at $31.7M in Q4 2025.
  • 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.